



## 20 ABSTRACT

21 Eritrea is the first African country to switch away from exclusive use of HRP2-based RDTs for  
22 the detection of *P. falciparum* due to high prevalence of *pfhrp2/3*-deleted *P. falciparum*  
23 parasites causing false-negative RDT results. While heavy reliance on malaria RDTs played a  
24 significant role in the rapid expansion of *pfhrp2/3*-deleted parasites in Eritrea, we  
25 hypothesize that the use of antimalarial (artesunate-amodiaquine) may have also  
26 contributed to their spread. We conducted a retrospective investigation of mutations in the  
27 propeller domain of the *P. falciparum kelch13* gene in samples collected in 2016 (n=50) from  
28 the Northern Red Sea Zone before the RDT switch away from HRP2-RDTs and in samples  
29 collected in 2018-2020 (n=587) from the Gash Barka, Anseba and Debub Zones after the  
30 RDT switch. No mutations were identified in the 2016 samples. However, in 2018-2019  
31 samples, we detected five different single non-synonymous mutations. The most prevalent  
32 mutation was *pfk13* R622I, which was detected in samples collected from all health centres,  
33 with an overall prevalence of 11.9% (ranging from 5.9% to 28%). Parasites carrying the  
34 R622I mutation have diverse microsatellite marker haplotypes, indicating that they had  
35 evolved multiple times from different genetic backgrounds. The prevalence *pfk13* R622I was  
36 significantly higher in single *pfhrp3*-deleted parasites (18.0%) compared to parasites without  
37 *pfhrp2/3* deletions (6.2%) and dual *pfhrp2/3*-deleted parasites (9.0%), suggesting  
38 association between the *pfk13* R622I mutation and the *pfhrp2/3* deletions in Eritrea.  
39 Continuous monitoring the trends in *pfhrp2/3* and *pfk13* mutants is needed to inform  
40 effective malaria management strategies in Eritrea.

41

42 **Keywords.** *P. falciparum*; RDTs; *pfhrp2* and *pfhrp3* deletions; HRP2; artemisinin  
43 combination therapies (ACTs); artemisinin resistance; *P. falciparum Kelch13* gene.

## 44 BACKGROUND

45 Eritrea , located in the Horn of Africa, experiences low and seasonal transmission of both *P.*  
46 *falciparum* and *P. vivax* malaria<sup>1</sup>. In 2012, the Eritrean National Malaria Control Programme  
47 (NMCP) successfully implemented a range of malaria interventions, including integrated  
48 vector control, the introduction of quality malaria RDT, and the deployment of artemisinin  
49 combination therapy (ACT)<sup>2</sup>. However, between 2015- 2020, malaria incidence and  
50 mortality rates increased by more than 40%<sup>1</sup>. This resurgence can be attributed, in part, to  
51 the emergence of mutant parasites capable of evading diagnostic tests and the  
52 development of partial resistance to artemisinin drugs among the parasites<sup>3</sup>.

53 In 2006, Eritrea introduced a HRP2-based combo RDT as a diagnostic tool for case malaria  
54 management. However, within the span of a decade, the country reported a high  
55 prevalence (62.0%) of *P. falciparum* parasites carrying *pfhrp2/3* gene deletions causing high  
56 rates of false negative HRP2-RDT results among symptomatic patients<sup>4,5</sup>, making Eritrea one  
57 of the countries severely impacted by these *pfhrp2/3*-deleted parasites. As a result, in 2016,  
58 Eritrea switched from HRP2-based RDTs to non-HRP2-based alternatives<sup>6</sup>. In 2019,  
59 approximately 2.5 years after the RDT switch, while the prevalence of parasites with gene  
60 deletions remains high the prevalence of parasites with dual *pfhrp2/3* deletions, a primary  
61 contributor to false negative RDT results, was much lower at multiple survey sites compared  
62 to that at the original sites<sup>6</sup>.

63 In 2007, following the introduction of RDTs, the Eritrean NMCP made a decision to switch  
64 the first line treatment of uncomplicated *P. falciparum* malaria from chloroquine and  
65 sulphadoxine/pyrimethamine (CQ-SP) to the ACT artesunate-amodiaquine (AS-AQ) due to a  
66 high treatment failure rate associated with CQ-SP<sup>7</sup>. To monitor the efficacy of AS-AQ, as  
67 recommended by WHO, therapeutic efficacy studies (TES) have been conducted within the  
68 country. These studies, conducted at various sentinel sites, have consistently demonstrated  
69 that AS-AQ exhibited efficacy rates exceeding 90% on day 28 in all sites<sup>8-10</sup>, however, the  
70 patient Day-3 parasite positive rate has increased between 2016 and 2019<sup>10</sup>.

71 In addition to TES, surveillance was undertaken to monitor molecular markers associated  
72 with partial artemisinin resistance, point mutations in *P. falciparum kelch13* gene (*pfk13*), as

73 well as resistance to CQ (mutations in *pfprt*) and AQ (mutations in *pfprt* and *pfmdr1*). These  
74 surveillance activities were conducted in the Gash Barka, Medefera and Debub Zones  
75 between 2013-2014<sup>11,12</sup> and in Gash Barka and Northern Red Sea Zones between 2016-  
76 2019<sup>10</sup>. The findings from these surveillance efforts supported the TES results. While high  
77 prevalence of AQ resistance-associated alleles of *pfprt* (CVIET haplotype) and *pfmdr1* (Y184F  
78 and N86Y) were continuously detected, prevalence of *pfk13* mutations was low in 2013-  
79 2014, with a single R622I and T535M detected among 119 samples from Gash Barka, as  
80 determined through deep amplicon sequencing. However, a recent report showed that the  
81 prevalence of *pfk13* R622I mutation in isolates before treatment reached 8.6% in 2016 and  
82 increased to 21.0% in 2019<sup>10</sup>.

83 The *pfk13* R622I mutation was first reported in a single sample collected from Zambia during  
84 the years 2012-2014, as part of a broader study on the global distribution of *pfk13*  
85 mutations<sup>13</sup>. Subsequently, it was reported in two individual samples collected from  
86 Mozambique and Somalia<sup>14</sup>. In Northern Ethiopia, specifically in a town close to the border  
87 with Sudan, the prevalence of R622I was found to be 2.4% (3/25) in samples collected  
88 during 2013-2014<sup>15</sup>. This prevalence increased to 9.3% (8/86) in samples collected between  
89 2017 and 2018, indicating an expansion of the mutant in the area<sup>16</sup>. The R622I mutation has  
90 been shown to possibly affect the function of *pfk13* by molecular modelling<sup>15</sup>, and it has  
91 recently been reported to associate with higher risk of day-3 positivity and recrudescence  
92 following ACT treatment in Eritrea TES<sup>10</sup>. In gene-edited parasites, the R622I mutation  
93 confers low levels of resistance to artemisinin in vitro<sup>10</sup>.

94 While existing data suggest that the major driving force behind the high prevalence of  
95 *pfhrp2/3* deletions in Eritrea was likely due to the use of HRP2-based RDTs <sup>6</sup>, it is important  
96 to consider that several other factors might also contribute to the rapid increase of the  
97 parasites in the country. Theoretically, various mechanisms such as fitness gains, the  
98 development of drug resistance, and the absence of host immunity could all confer selective  
99 advantages to *pfhrp2/3*-deleted parasites when facing competition or encountering  
100 pressures from drug and immune system from the host. Conversely, the evasion of  
101 detection by RDTs due to *pfhrp2/3* deletions could also contribute to the survival and spread  
102 of drug resistant parasites. Consequently, *pfhrp2/3*-deleted parasites could spread in  
103 communities by hitch-hiking alongside the spread of drug-resistant parasites or a newly

104 emerging strains for which there is no pre-existing immunity in the community<sup>17</sup>.  
105 Conversely, drug resistant parasites might be similarly spread by hitch-hiking on the spread  
106 of *pfhrp2/3*- deleted parasites. The interplay between *pfhrp2/3*-deleted parasites and drug-  
107 resistant parasites is not clear, with both phenomena potentially influencing each other's  
108 spread and survival within communities.

109 In this study, we conducted a retrospective analysis *pfk13* mutations using existing samples  
110 collected from symptomatic patients seeking care more than 10 health facilities across 3  
111 Zones as part of previous studies. These samples were originally collected during three  
112 separate periods: during 2016 survey and the 2019-2020 survey, both surveys aimed at  
113 assessing prevalence of *pfhrp2/3* deletions; and during the 2018-2019 severe malaria study.  
114 Our primary objective was to investigate the prevalence of *pfk13* mutations in Eritrea and  
115 explore their potential relationship with *pfhrp2/3* deletions. The study contributes valuable  
116 insights into the potential selective forces the influence the relative abundance of diagnostic  
117 and drug-resistant parasites in the Eritrean context.


## 118 **METHODS**

### 119 **Source and number of samples**

120 In this retrospective study, patient samples were collected from two different studies:

121 1) Surveillance of *pfhrp2/3* deletions: This study incorporated samples obtained from two  
122 cross-sectional surveys designed to investigate the prevalence of *pfhrp2/3* deletion  
123 among symptomatic patients (referred to as “survey samples”). The first survey was  
124 conducted in 2016 at two hospitals in the Red Sea Zone, namely Ghindae and Massawa<sup>4</sup>,  
125 from which 50 samples were obtained. A follow up *pfhrp2/3* deletion survey took place  
126 during 2019-2020, encompassing nine hospitals/Health Centres spanning three zones:  
127 Gash Baka (Agordat, Shambuko, Tesseney, Tekobmia and Barentu), Anseba (Keren and  
128 Hagaz) and Debub (Mendefera and Maimine)<sup>6</sup>. This border survey collected 714 *P.*  
129 *falciparum* samples, with 417 (representing 66.0%) of these samples were used in the  
130 present study.

131 2) The severe malaria study. The study was conducted during the period of 2018-2019 with  
132 the aim of investigating the impact of *pfhrp2/3* deletions on clinical outcomes in Eritrea.  
133 A total of 116 *P. falciparum* infected blood samples (referred to as “severe malaria  
134 samples”) were collected from three distinct zones: Gash Barka (Agordat and Barentu),  
135 Anseba (Keren) and Debub (Menderfera, Emni-Haily, Areza, Dubarwa, and Mulki).  
  
136 For data analysis, survey and severe malaria samples, collected between 2018 and 2020,  
137 were merged according to health facilities where they were collected. In cases where  
138 less than five samples were obtained from each of the four health facilities in the Debub  
139 zone (Areza, Dubarwa, Emni-Haily and Mulki), these were consolidated into a single  
140 group (A/D/E/M). The collection sites can be visualised on the map provided Figure 1.



141  
142 Figure 1. Map of Eritrea showing locations of health facilities (red crosses) where  
143 samples were collected from (HP: hospital; HC: health centre).

144 **Genomic DNA and Plasmodium infection**

145 Genomic DNA extraction from survey samples had been previously described in earlier  
146 publications<sup>4,6</sup>. Additionally, genomic DNA were isolated from severe malaria samples using  
147 robotic system, following the same protocol as previously reported<sup>18</sup>.

### 148 **Amplification and sequencing *pfk13***

149 For survey samples, which included 50 samples from the 2016, and 417 DNA samples  
150 randomly selected from different *pfhrp2/3* status groups of 2019-2020, the propeller region  
151 of the *pfk13* gene (codons 435 to 680) was amplified using published primers and  
152 conditions<sup>19</sup>. Subsequently, amplified fragments were then sequenced from both ends by  
153 Sanger sequencing using BigDye reagents.

154 For severe malaria samples, A 1033bp fragment, spanning from codon 380 to 724 of the  
155 propeller region of *pfk13* amino acid sequences, was amplified using forward primer  
156 (TAAGTGGGAAGACATCATGTAACCAGAGA) and reverse primer  
157 (GTCTAAAACCAAGTGGGAACAAAAATCGT). Amplification of DNA was performed in a 25 µl  
158 reaction on thermal cycler (PCRmax, UK). The reaction mixture included 5 µl of extracted  
159 genomic DNA, 200 nM of each primer, 3 mM of MgCl<sub>2</sub>, 300 µM of each dNTP (Meridian,  
160 UK), 1X NH<sub>4</sub> reaction buffer (Meridian, UK) and 1 U of the NEB High Fidelity Q5 polymerase.  
161 The PCR conditions consisted of 95°C for 3 min, followed by 40 cycles of denaturation at  
162 95°C for 30 sec, annealing at 55°C for 60 sec, and extension at 72°C for 2 min. The amplified  
163 fragments were visualised using gel electrophoresis<sup>18</sup>. Subsequently, amplicon pooling and  
164 cleaning were carried out as previously described<sup>20</sup>. Library preparation and adaptor ligation  
165 were carried out using the Oxford Nanopore native barcoding kit (sqk-nbd-112-96) in  
166 accordance with the manufacturer's protocol (Oxford Nanopore, UK).

### 167 **Haplotype diversity and genetic relatedness.**

168 A total of seven neutral microsatellite markers (TA1, PolyA, PfPK2, TA109, 2490, 313, and  
169 383) were analysed as part of previous studies<sup>4,6</sup>. Haplotype data were available for 184  
170 survey samples, which were included in the current study - 50 from 2016 and 134 from  
171 2019/2020. To assess the genetic diversity and genetic relatedness of parasite haplotypes  
172 with different *pfk13* variants, we employed FSTAT and PHYLOViZ online software (version  
173 1.1) using instructions provided by the developers.

## 174 ***pfhrp2* and *pfhrp3* gene status**

175 The status of *pfhrp2* and *pfhrp3* gene in all samples was evaluated using a multiplex qPCR  
176 method. This method simultaneously amplifies a fragment of the *pfhrp2* and *pfhrp3* exon2,  
177 pLDH and human tubulin gene<sup>21</sup>. Published primer and probe sequences, as well as PCR  
178 reagents and conditions, were used for assessing severe malaria samples. For survey samples,  
179 we introduced some modifications: quencher on the *pfhrp2* (BHQ1) and *pfl dh* (BHQ2)  
180 probes were adjusted, Quantinova multiplex PCR kit master mix (QIAGEN) was utilized, and  
181 the Mic qPCR cycler (Bio Molecular Systems) was employed. In the classification of samples  
182 as having a *pfhrp2* and/or *pfhrp3* deletion, a threshold was set at  $\Delta Cq$  ( $Cq_{pfhrp2} - Cq_{pfl dh}$   
183 and/or  $Cq_{pfhrp3} - Cq_{pfl dh}$ )  $\geq 3$ <sup>21</sup>. Samples exhibiting  $Cq_{pfl dh}$  values exceeding 35 cycles were  
184 deemed indeterminate due to insufficient DNA for analysis.

## 185 **Quantification of parasite density**

186 To determine the quantity of parasite DNA (pg/ $\mu$ L) in survey samples, we relied on the  $Cq_{pfl dh}$   
187 value of each sample in comparison to a 3D7 standard curve. This standard curve was  
188 generated using serial dilutions of 3D7 DNA at 1, 0.1, 0.01 and 0.001ng/ $\mu$ L, and it was  
189 included in each multiplex qPCR run. In case of the severe malaria samples, parasite density  
190 estimation was conducted against the WHO International Standard<sup>22</sup>, as previously  
191 described<sup>18</sup>.

## 192 **Ethics considerations**

193 The surveys of *pfhrp2/3* deletions were granted approval by the Eritrean MOH Research and  
194 Ethical Committee. Laboratory analyses on collected samples received approval from the  
195 Departments of Defence and Veterans Affairs Human Research Ethics Committee (DDVA  
196 HREC 15-004). Additionally, the severe malaria study was granted approval by LSHTM Ethics  
197 Review Committee (#11979).

## 198 **Data analysis**

199 Sequence analysis: Sequences of *Pfk13* from survey samples were aligned using  
200 MEGA7.0.26<sup>23</sup>. SNPs were identified by comparing these alignments with *pfk13* sequence in  
201 3D7 (PF3D7\_1343700). For severe malaria samples, amplicon reads were analysed using the



202 python language and well-established bioinformatics tools as described previously, with  
203 some slight modifications<sup>24</sup>. Sequencing alignment was performed using minimap2  
204 software<sup>25</sup>. Mutation prevalence analysis was conducted using the R-package vcfR (version  
205 1.12.0) and plyr (version 1.8.6).

206 Statistical analysis: To compare mutation prevalence and proportions between sample  
207 groups, chi-squared test and odds ratio (OR) analysis were employed. Additionally,  
208 comparisons of median parasite DNA concentrations and parasite densities among sample  
209 groups were carried out using Mann-Whitney test.

210

## 211 **RESULTS**


### 212 **Prevalence of *pfk13* mutation**

213 Sequence analysis of 50 samples collected in 2016 revealed a wild type *pfk13* gene in all  
214 samples, indicating the absence of mutations. In contrast, analysis of sequences obtained  
215 from the combined pool of 587 survey and severe malaria samples collected between 2018  
216 and 2020) samples revealed five different non-synonymous mutations: E605K, R622I,  
217 N657K, K658E and S679L. Importantly, each mutant *pfk13* sequence contain only a single  
218 amino acid mutation within the propeller region, with no combinations observed. Among  
219 these mutations, the R622I mutation had the highest overall prevalence of 11.9% (70/587).  
220 Following this, N657K the N657K mutation was observed in 0.3% of the samples (2/471).  
221 Meanwhile, the E605K, K658E and S679L mutations were each detected in a single sample,  
222 giving a 0.2% (1/587) prevalence (Supplemental Table 1).

### 223 **Distribution of *pfk13* mutations**

224 The samples carrying the E605, K658E, S679L and N657K mutations were exclusively  
225 collected from the Gash Barka zone. However, the R622I mutation was identified in samples  
226 collected from all health facilities in the three zones with a prevalence exceeding higher  
227 than 10% in eight of these health facilities (Figure 2, Supplemental Table 1). The prevalence  
228 of R622I was highest in Hagaz hospital (28.0%, 7/25) in the Anseba zone, while the lowest  
229 prevalence was observed in samples obtained from Mendefera Hospital (5.9%, 3/51) in the

230 Debub zone. The prevalence of R622I was significantly higher in Hagaz compared to  
 231 Mendefera (Chi-squared test,  $p=0.0078$ ), Keren (9.9%, Chi-squared test  $p=0.0207$ ) and  
 232 Barentu ( $p=0.0341$ ). However, no statistical differences were observed at the zone level  
 233 ( $p>0.05$ ). The prevalence for R622I were 11.9% (44/370) in Gash Barka, 13.8% (16/116) in  
 234 Anseba and 9.9% (10/101) in Debub zone (Figure 2, Supplemental Table 1).




235  
 236 **Figure 2.** Prevalence of K13 mutations among health facilities (years 2018 - 2020), zones  
 237 and overall. \* $p<0.05$ ; \*\* $p<0.01$ .

238 **Haplotype diversity and genetic relatedness of *pfk13* R622I mutants**

239 To gain insight into whether the R622I mutants shared a common ancestry and to assess if  
 240 they were undergoing expansion, we analysed microsatellite haplotypes obtained from  
 241 previous studies<sup>4,6</sup>. We examined 184 survey samples, of which 26 carried the *pfk13* R622I  
 242 mutation. Among these 26 samples, we identified 23 unique haplotypes, with all but two  
 243 were found in one sample each. The remaining two haplotypes were shared between two  
 244 and three samples (Supplemental Table 2). In contrast, among the remaining 158 samples  
 245 with the wild-type 622R, we identified 87 unique alleles. The overall genetic diversity,  
 246 represented by  $H_E$  values, among R622I mutants was calculated at 0.4774 (95% CI: 0.1873 –  
 247 0.7676), which is slightly lower than that of the 622R wild-type parasites (0.5773, 95% CI:

248 0.3760 – 0.7786). However, these difference was not statistically significant (FSTAT,  
249  $p=0.0500$ , determined after 20 permutations, Supplemental Table 3).

250 Our genetic relatedness analysis revealed that while 15 of the 23 R622I mutant haplotypes  
251 were closely related within a cluster, the remaining eight mutant haplotypes were not  
252 closely related to each other, suggesting independent genetic origins (Figure 3). These  
253 findings indicate parasites carrying R622I mutation had evolved from different genetic  
254 backgrounds, involving both clonal expansion and independent emergence.




255  
256 **Figure 3. Genetic relatedness of parasites carrying the *pfk13* R622I mutation (in Pink) or**  
257 **wild-type 622R (in Green):** A cut-off of two was applied, meaning that only parasite  
258 haplotypes with five or more identical alleles of the seven markers tested were linked  
259 together.

### 260 **Parasite density and *pfk13* mutations**

261 To investigate whether the *pfk13* mutations had impact on parasite fitness, we analysed the  
262 parasite densities estimated for the survey samples, and we found no significant difference  
263 in median parasite DNA concentration between samples carrying the R622I mutation and  
264 those with the wild-type 622R (25.15, 95%CI: 18.55 – 40.72 vs 23.71, 95%CI: 18.55 – 28.23,


265  $p=0.6771$ , Figure 4). Similarly, our analysis of severe malaria samples indicated comparable  
266 ( $p=0.9367$ ) median parasite densities (4674, 95%CI: 419.0 – 11430 vs 4242, 95%CI: 2436 -  
267 5444 parasites/ $\mu\text{L}$ ) between the two *pfk13* genotypes (Figure 4). These results suggest that  
268 the presence of *pfk13* mutations did not lead to significant differences in parasite density.



269  
270 **Figure 4.** Comparison of parasite density between *pfk13* R622I mutant and wild-type 622R  
271 parasites. A: Concentration of parasite DNA in survey samples estimated by qPCR against a  
272 standard curve. B: Parasite densities in severe malaria samples estimated by qPCR against  
273 an International standard. Horizontal and vertical bars represent median and inter-quartile  
274 range, respectively.

#### 275 Proportion of samples with *pfhrp2/3* deletions

276 Of the total 587 samples collected between 2018 and 2020 with *pfk13* sequences, 578 had  
277 *pfhrp2* and *pfhrp3* status determined. Among these 17 samples (2.9%) displayed a single  
278 *pfhrp2* deletion, 255 samples (44.1%) exhibited a single *pfhrp3* deletion, 145 samples  
279 (25.1%) with double *pfhrp2/3* deletion, and 161 samples (27.9%) showed no deletion in  
280 either *pfhrp2* or *pfhrp3* (Figure 5, Supplemental Table 4). The remaining nine samples could  
281 not have their *pfhrp2/3* status determined due to insufficient DNA.



282  
283 **Figure 5.** Proportion of samples with and without *pfhrp2* and *pfhrp3* deletions.

284 **Association of *pfk13* R622I mutation with *pfhrp2/3* deletions**

285 Table 1 provides a summary of *pfk13* mutations observed in samples with varying *pfhrp2/3*  
286 status. Samples with single *pfhrp3* deletion, in addition to having four out of five *pfk13*  
287 mutations, also showed a significantly higher prevalence of R622I mutation (18.0%, 46/255)  
288 compared to samples without *pfhrp2/3* deletions (6.2%, 10/161, OR = 3.89, p = 0.0006), or  
289 those with dual *pfhrp2/3* deletions (9.0%, 13/145, OR = 2.23, p=0.0183) (Table 1,  
290 Supplemental Figure 1A).

291 Out of the 70 samples with R622I mutations, one sample (1.4%) was classified as having a  
292 single *pfhrp2* deletion, 46 samples (65.7%) showed single *pfhrp3* deletion, 13 samples  
293 (18.6%) had dual *pfhrp2/3* deletion and 10 samples (14.3%) had no *pfhrp2/3* deletions  
294 (Supplemental Figure 1B). In the remaining 508 wild type 622R samples however, the  
295 proportions of single *pfhrp2*, single *pfhrp3*, dual *pfhrp2/3* deletion and no deletions were:  
296 3.1%, 41.1%, 26.0%, and 30.7% respectively (Supplemental Figure 1B). The proportion of  
297 single *pfhrp3* deletion was significantly higher (p<0.0001), while the proportion of no  
298 deletions (p= 0.0071) was significantly lower in the R622I mutant compared to 622R wild  
299 type (Supplemental Figure 1B).

300 **Table 1.** Number and percentage of *pfK13* mutations in samples with varying *pfhrp2* and *pfhrp3* gene status. P-value, confidence interval, CI;  
 301 and Odds Ratio (OR) are single *pfhrp3* deletion compared to other genotypes.

| <i>pfhrp2/3</i> status   | No. seq. | E605K |      | R622I |       |                          | N657K |      | K658E |      | S679L |      | WT  |       |
|--------------------------|----------|-------|------|-------|-------|--------------------------|-------|------|-------|------|-------|------|-----|-------|
|                          |          | n     | %    | n     | %     | p-value,[ CI], OR        | n     | %    | n     | %    | n     | %    | n   | %     |
| Single <i>pfhrp2</i> del | 17       | 0     | 0.0% | 1     | 5.9%  | 0.322, [0.52-150], 3.51  | 0     | 0.0% | 0     | 0.0% | 0     | 0.0% | 16  | 94.1% |
| Single <i>pfhrp3</i> del | 255      | 0     | 0.0% | 46    | 18.0% |                          | 2     | 0.8% | 1     | 0.4% | 1     | 0.4% | 205 | 80.4% |
| Dual <i>pfhrp2/3</i> del | 145      | 0     | 0.0% | 13    | 9.0%  | 0.0183,[1.13-4.68], 2.23 | 0     | 0.0% | 0     | 0.0% | 0     | 0.0% | 132 | 91.0% |
| No deletion              | 161      | 1     | 0.6% | 10    | 6.2%  | 0.0006,[1.59-7.61], 3.89 | 0     | 0.0% | 0     | 0.0% | 0     | 0.0% | 150 | 93.2% |
| Total                    | 578      | 1     | 0.2% | 70    | 12.1% |                          | 2     | 0.3% | 1     | 0.2% | 1     | 0.2% | 503 | 87.0% |

302

## 303 DISCUSSION

304 This study reports the prevalence and trends of *pfk13* mutations in the *P. falciparum*  
305 population in Eritrea from 2016 to 2020. Additionally, the study explores any potential  
306 association between these mutations and *pfhrp2/3* deletions. By analysing these factors, the  
307 study aims to gain a better understanding of the underlying factors influencing the  
308 prevalence of *pfk13* mutations and *pfhrp2/3* gene deletions.

309 In 2016, a decade after widespread use of HRP2-based RDTs and AS-AQ in Eritrea, 62% of  
310 the patients were infected with parasites lacking both *pfhrp2* and *pfhrp3* genes, rendering  
311 them undetectable by HRP2-based RDTs<sup>4</sup>. Notably, no mutation was detected in the *pfk13*  
312 gene in these samples. Despite the relatively small sample size, the data suggest that the  
313 *pfk13* mutations were either absent or present as a minor variants below the detection  
314 limit, indicating very low frequencies at the two study sites during the survey period. This  
315 finding aligns with an earlier study conducted in 2013/14, which reported a low prevalence  
316 (0.8%, 1/119) of the R622I mutation in samples collected in Agordat and Barentu in the Gash  
317 Barka Zone<sup>12</sup> despite difference in sample collection sites and sequencing technologies.  
318 Nevertheless, a more recent study reported a much higher prevalence (8.2%) of R622I  
319 mutation among 280 samples collected during the 2016 TES conducted in the Gash Barka  
320 Zone. This suggests that the distribution of R622I mutation was highly geographically  
321 heterogeneous in Eritrea in 2016.

322 In 2018-2020, two years after discontinuing the use HRP2-based RDTs, *pfk13* R622I  
323 mutations were identified in samples from all health facilities across three zones in Eritrea.  
324 The prevalence of this mutation ranged from 2.5% to 28% with a mean prevalence of 11.9%,  
325 and more than three-quarters of health facilities reported a prevalence exceeding 10%. In  
326 specific locations like Agordat and Barentu, the prevalence of R622I had reached 13.7%  
327 (13/95) and 11.0% (10/91), respectively, which is significantly higher than five years  
328 earlier<sup>12</sup>. The prevalence and wide distribution of R622I mutation detected in this study  
329 combined with that reported recently from TES<sup>10</sup> demonstrate the R622I mutation has  
330 become highly prevalent throughout of Eritrea since 2017. Microsatellite genotyping results  
331 revealed that the increase in R622I prevalence was due to a combination of clonal  
332 expansion of the mutant parasites and multiple independent emergences from different

333 genetic backgrounds, suggesting a complex evolutionary dynamics similar to that reported  
334 in Ethiopia<sup>26</sup>. It is likely that these mutations locally evolved in Eritrea rather than spreading  
335 from neighbouring countries such as Sudan and Ethiopia, as genetic analysis using the same  
336 haplotype data indicated differences between Eritrean parasite lineages, both with and  
337 without *pfhrp2/3* deletions, and those from Sudan and Ethiopia/ Djibouti<sup>27</sup>.

338 Interestingly, our study found that the R622I mutation was significantly enriched in single  
339 *pfhrp3*-deleted (*pfhrp2* positive) parasites and was relatively more prevalent in *pfhrp2/3*-  
340 deleted parasites in Eritrea. This observation, which was also reported from TES results<sup>10</sup> in  
341 Eritrea, contrasts with the findings in Ethiopia, where R622I was more prevalent in parasites  
342 without *pfhrp2/3* deletions<sup>26</sup>. This difference may be related to the types of RDTs used in  
343 these countries at the time of the survey. While both countries had high prevalence of  
344 *pfhrp2/3* deletions, Eritrea switched from HRP2-based RDTs to pLDH-based RDTs in 2016,  
345 whereas Ethiopia continued to use HRP2-based RDTs. We hypothesise a two-step evolution:  
346 an initial emergence of *pfhrp2/3* deletions under HRP2-based RDT selection pressure,  
347 followed by the multiple independent emergences of the *pfk13* R622I mutation in gene-  
348 deleted parasites under ACT selection pressure. In Eritrea, it is likely that *pfhrp2/3* deletion  
349 occurred first, given its higher prevalence compared to R622I. However, the driving force for  
350 a close association between *pfhrp3* deletion and *pfk13* R622I, and between *pfhrp2/3*  
351 deletion and *pfk13* R622I is not clear but may be related to fitness gains in parasites carrying  
352 both *pfhrp3* deletion and *pfk13* R622I mutations. While the data suggest that the mutation  
353 does not appear to be associated with parasite density in peripheral blood, it could  
354 potentially alter other characteristics such as transmissibility.

355 The influence of *pfhrp2/3* deletions on parasite fitness in infected individuals remains  
356 uncertain. Previous studies using genomic data from genetic crosses indicated no fitness  
357 cost, which reduces heritability associated with these deletions in the mosquito and liver  
358 stages<sup>28</sup>. However, contradictory *in vitro* results have demonstrated fitness costs<sup>29</sup>,  
359 suggesting these may be confined to the blood stages of the life cycle. These findings  
360 underscore the need for a deeper understanding of the interplay between drug resistance,  
361 *pfhrp2/3* deletions and parasite fitness in the evolution of *P. falciparum*.



362 The emergence of *P. falciparum* with *pfhrp2/3* deletions and *pfk13* mutations presents a  
363 dual-threat scenario, conferring resistance to some diagnostic measures and therapeutic  
364 interventions. Indications of potential co-occurrence between *pfhrp2/3* deletions and *pfk13*  
365 mutations have been documented, notably in Ethiopia. The findings in this study have shed  
366 light on instances of co-occurring *pfk13* R622I and *pfhrp2/3* variants in Eritrea<sup>26</sup>. At present,  
367 a well-established correlation between *pfhrp2/3* deletions and *pfk13* mutations, as well as  
368 their collective impact on parasite fitness, remains unclear. *In vitro* experimentations have  
369 indicated that the *pfk13* C580Y mutation entails modest fitness costs when accompanied by  
370 multicopy *pm2/3*, while it remains fitness-neutral in the presence of single *pm2/3* copies<sup>30</sup>.  
371 We hypothesise a comparable scenario of fitness cost interplay between *pfk13* mutations  
372 and *pfhrp2/3* deletions. Further studies are required to decipher the interaction between  
373 *pfhrp2/3* deletions and *pfk13* mutations.

374 This study has several notable strengths. Firstly, our study is the first to document the  
375 presence of *pfk13* R622I in two administrative zones (Anseba and Debub) and ten sub-zones  
376 in addition to zones and sub-zones reported previously (Mihreteab 2023). This observation  
377 signifies the expansion of *pfk13* R622I in Eritrean territory. Secondly, it is imperative to  
378 highlight that two of the newly identified sub-zones, Tesseney (located in close proximity to  
379 the Sudanese border) and Maimine (situated near the Ethiopian border), carry notable  
380 regional significance, requiring concerted regional response. Finally, the study's strength is  
381 underscored by the substantial sample size collected in 2019 compared to most recently  
382 published<sup>10</sup> for the same year. This sample size allows greater power for analysis of  
383 association between *pfhrp2/3* deletion and *pfk13* mutation. Overall, our study  
384 independently confirms the emergence, progress augmentation overtime and geographical  
385 expansion of *pfk13* R622I, along with *pfhrp2/3* deletions correlation within Eritrea context.

386 This study has certain limitations. Firstly, samples collected before 2016 and after RDT  
387 switch (2018-2020) were obtained from different health facilities and zones, limiting direct  
388 comparisons in the prevalence of *pfhrp2/3* deletions and *pfk13* mutations between the two  
389 time points. Secondly, sequencing of *pfk13* was conducted on a subset of samples collected  
390 between 2018 and 2020. However, as all samples from the severe malaria study and a  
391 representative subset of samples from the 2019 survey (including 66 – 88% of *pfhrp2/3*

392 deletion and 59% of no deletion samples) were sequenced, significant bias on the outcomes  
393 is unlikely. The study by Mihreteab et al. during the same timeframe using samples from TES  
394 reported comparable results, thereby confirming the validity of our own findings.  
395 Furthermore, this study focused on mutations within the propeller domain of the *pfk13*,  
396 excluding possible mutations outside of the propeller domain that may contribute to  
397 artemisinin resistance and interaction with gene deletions.

398 The R622I mutation has primarily been reported in the Horn of Africa region, where very  
399 high *pfhrp2/3* deletion prevalence was previously reported<sup>4,6,27,31,32</sup>. Eritrea and Sudan  
400 introduced AS-AQ, while Ethiopia and Djibouti use AL as first line therapy for uncomplicated  
401 *P. falciparum* malaria. Our study in Eritrea demonstrates the expansion of *pfk13* R622I  
402 mutations in the country, with the mutation being enriched in single *pfhrp3*-deleted  
403 parasites. While the emergence of *pfk13* R622I is likely associated with increased ACT use  
404 and reduced transmission, its interaction with *pfhrp2/3* deletions remains unclear. Although  
405 R622I has been established as a confirmed molecular marker of partial artemisinin  
406 resistance in Eritrea, additional research is necessary to ascertain its applicability as a  
407 molecular marker in neighbouring regions, where *P. falciparum* strains with distinct genetic  
408 backgrounds are prevalent. Continued monitoring of the trends in *pfhrp2/3* deletions and  
409 *pfK13* R622I mutations in Eritrea and the Horn of Africa with and without HRP2-based RDT  
410 uses will provide insight into the relationship between *pfhrp2/3* deletions and *pfK13* R622I  
411 mutations, essential for the success of future control and elimination efforts.

## 412 **Notes**

413 **Acknowledgement.** The authors would like to thank patients for their  
414 participation of the studies. We would also like to thank Kathleen Krupinski from the WHO  
415 GIS Centre for Health for map production.

416 **Disclaimer.** The views expressed in this article are those of the authors and do not  
417 necessarily reflect the official policy or position of the Australian Department of Defence,  
418 nor the WHO, or the Ministry of Health, Eritrea.

419 **Financial support.** This laboratory work was supported by the US DoD Armed Forces  
420 Health Surveillance Division, Global Emerging Infections Surveillance Branch (AFHSD/GEIS),  
421 PROMIS ID P0111\_22\_AF and Wellcome's Institutional Strategic Support Fund to KBB  
422 (204928/Z/16/Z) The funders had no role in study design, data collection and analysis,  
423 decision to publish, or preparation of the manuscript.

424 **Potential conflicts of interests.** All authors: No reported conflicts.

425 **Author Contributions.** SM, KB, JC and QC designed the study. KA, IM, DLF and DS  
426 conducted laboratory experiments, acquired data and performed initial data analysis. CS  
427 contributed materials and data analysis. SM organised and managed field surveys, sample  
428 collection and epidemiological analysis. KB and QC analysed data and drafted the  
429 manuscript. All authors participated in manuscript review and revision, and approved the  
430 final manuscript.

#### 431 **Author contact details**

432 Selam Mihreteab: [smuqubay@gmail.com](mailto:smuqubay@gmail.com)

433 Karen Anderson: [karena015@gmail.com](mailto:karena015@gmail.com)

434 Irene Molina - de la Fuente: [i.molina@edu.uah.es](mailto:i.molina@edu.uah.es)

435 Colin J Sutherland: [Colin.Sutherland@lshtm.ac.uk](mailto:Colin.Sutherland@lshtm.ac.uk)

436 David Smith: [david.smith77@defence.gov.au](mailto:david.smith77@defence.gov.au)

437 Jane Cunningham: [cunninghamj@who.int](mailto:cunninghamj@who.int)

438 Khalid B Beshir: [Khalid.Beshir@lshtm.ac.uk](mailto:Khalid.Beshir@lshtm.ac.uk)

439 Qin Cheng: [qin.cheng@defence.gov.au](mailto:qin.cheng@defence.gov.au)

## 440 References

- 441 1 WHO. World malaria report 2021. Geneva. (2021).
- 442 2 Berhane, A. *et al.* Gains attained in malaria control coverage within settings earmarked for  
443 pre-elimination: malaria indicator and prevalence surveys 2012, Eritrea. *Malar J* **14**, 467,  
444 doi:10.1186/s12936-015-0992-9
- 445 10.1186/s12936-015-0992-9 [pii] (2015).
- 446 3 WHO. in *World Health Organization, Geneva, Switzerland Vol.*  
447 <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022>  
448 (2022).
- 449 4 Berhane, A. *et al.* Major Threat to Malaria Control Programs by *Plasmodium falciparum*  
450 Lacking Histidine-Rich Protein 2, Eritrea. *Emerg Infect Dis* **24**, 462-470,  
451 doi:10.3201/eid2403.171723 (2018).
- 452 5 Berhane, A. *et al.* Rapid diagnostic tests failing to detect *Plasmodium falciparum* infections in  
453 Eritrea: an investigation of reported false negative RDT results. *Malar J* **16**, 105,  
454 doi:10.1186/s12936-017-1752-9 (2017).
- 455 6 Mihreteab, S. *et al.* Epidemiology of mutant *Plasmodium falciparum* parasites lacking  
456 histidine-rich protein 2/3 genes in Eritrea 2 years after switching from HRP2-based RDTs. *Sci*  
457 *Rep* **11**, 21082, doi:10.1038/s41598-021-00714-8 (2021).
- 458 7 Ghebremeskel, T. Therapeutic efficacy of sulfadoxine/pyrimethamine plus chloroquine and  
459 artesunate plus amodiaquine for the treatment of uncomplicated falciparum malaria. *J.*  
460 *Eritrean Med. Assoc.* , 2, 14–16. , doi:<https://doi.org/10.4314/jema.v2i1.52701> (2007).
- 461 8 Mihreteab, S. Therapeutic efficacy study on artesunate + Amodiaquine (AS + AQ) for the  
462 treatment of uncomplicated *Plasmodium falciparum* (Pf) malaria in Eritrea. *J. Eritrean Med.*  
463 *Assoc*, 1, 9–12. (2014).
- 464 9 Mohammed, A. O., Tewolde, S., Estifanos, D., Tekeste, Y. & Osman, M. H. Therapeutic  
465 efficacy of artesunate - amiodaquine for treating uncomplicated falciparum malaria at  
466 Ghindae Zonal Referral Hospital, Eritrea. *Acta Trop* **177**, 94-96,  
467 doi:10.1016/j.actatropica.2017.10.004 (2018).
- 468 10 Mihreteab, S. *et al.* Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in  
469 Eritrea. *N Engl J Med* **389**, 1191-1202, doi:10.1056/NEJMoa2210956 (2023).
- 470 11 Menegon, M., Nurahmed, A. M., Talha, A. A., Nour, B. Y. & Severini, C. Molecular  
471 surveillance of antimalarial drug resistance related genes in *Plasmodium falciparum* isolates  
472 from Eritrea. *Acta Trop* **157**, 158-161, doi:10.1016/j.actatropica.2016.02.007 (2016).
- 473 12 L'Episcopia, M. *et al.* Targeted deep amplicon sequencing of *kelch 13* and cytochrome b in  
474 *Plasmodium falciparum* isolates from an endemic African country using the Malaria  
475 Resistance Surveillance (MaRS) protocol. *Parasit Vectors* **13**, 137, doi:10.1186/s13071-020-  
476 4005-7 (2020).
- 477 13 Menard, D. *et al.* A Worldwide Map of *Plasmodium falciparum* K13-Propeller  
478 Polymorphisms. *N Engl J Med* **374**, 2453-2464, doi:10.1056/NEJMoa1513137 (2016).
- 479 14 Wang, X. *et al.* Molecular surveillance of *Pfcr*t and *k13* propeller polymorphisms of imported  
480 *Plasmodium falciparum* cases to Zhejiang Province, China between 2016 and 2018. *Malar J*  
481 **19**, 59, doi:10.1186/s12936-020-3140-0 (2020).
- 482 15 Bayih, A. G. *et al.* A Unique *Plasmodium falciparum* K13 Gene Mutation in Northwest  
483 Ethiopia. *Am J Trop Med Hyg* **94**, 132-135, doi:10.4269/ajtmh.15-0477

- 484 ajtmh.15-0477 [pii] (2016).  
485 16 Alemayehu, A. A. *et al.* Expansion of the *Plasmodium falciparum* Kelch 13 R622I mutation in  
486 Northwest Ethiopia. *Research Square*, doi:<https://doi.org/10.21203/rs.3.rs-171038/v1>  
487 (2021).  
488 17 Valdivia, H. O. *et al.* Spatiotemporal dynamics of *Plasmodium falciparum* histidine-rich  
489 protein 2 and 3 deletions in Peru. *Sci Rep* **12**, 19845, doi:10.1038/s41598-022-23881-8  
490 (2022).  
491 18 Beshir, K. B. *et al.* *Plasmodium falciparum* parasites with histidine-rich protein 2 (*pfhrp2*) and  
492 *pfhrp3* gene deletions in two endemic regions of Kenya. *Sci Rep* **7**, 14718,  
493 doi:10.1038/s41598-017-15031-2  
494 10.1038/s41598-017-15031-2 [pii] (2017).  
495 19 Arieu, F. *et al.* A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria.  
496 *Nature* **505**, 50-55, doi:10.1038/nature12876  
497 nature12876 [pii] (2014).  
498 20 Olukosi, A. Y. *et al.* Baseline prevalence of molecular marker of sulfadoxine/pyrimethamine  
499 resistance in Ebonyi and Osun states, Nigeria: amplicon deep sequencing of dhps-540. *J*  
500 *Antimicrob Chemother* **78**, 788-791, doi:10.1093/jac/dkad011 (2023).  
501 21 Grignard, L. *et al.* A novel multiplex qPCR assay for detection of *Plasmodium falciparum* with  
502 histidine-rich protein 2 and 3 (*pfhrp2* and *pfhrp3*) deletions in polyclonal infections.  
503 *EBioMedicine* **55**, 102757, doi:10.1016/j.ebiom.2020.102757 (2020).  
504 22 Padley, D. J., Heath, A. B., Sutherland, C., Chiodini, P. L. & Baylis, S. A. Establishment of the  
505 1st World Health Organization International Standard for *Plasmodium falciparum* DNA for  
506 nucleic acid amplification technique (NAT)-based assays. *Malar J* **7**, 139, doi:10.1186/1475-  
507 2875-7-139  
508 1475-2875-7-139 [pii] (2008).  
509 23 Kumar, S., Stecher, G. & Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis  
510 Version 7.0 for Bigger Datasets. *Mol Biol Evol* **33**, 1870-1874, doi:10.1093/molbev/msw054  
511 (2016).  
512 24 Nolder, D. *et al.* Failure of rapid diagnostic tests in *Plasmodium falciparum* malaria cases  
513 among travelers to the UK and Ireland: Identification and characterisation of the parasites.  
514 *Int J Infect Dis* **108**, 137-144, doi:10.1016/j.ijid.2021.05.008 (2021).  
515 25 Li, H. New strategies to improve minimap2 alignment accuracy. *Bioinformatics* **37**, 4572-  
516 4574, doi:10.1093/bioinformatics/btab705 (2021).  
517 26 Fola, A. A. *et al.* Clonal spread of *Plasmodium falciparum* candidate artemisinin partial  
518 resistance Kelch13 622I 1 mutation and co-occurrence with *pfhrp2/3* deletions in Ethiopia  
519 *medRxiv preprint* doi: <https://doi.org/10.1101/2023.03.02.23286711> (2023).  
520 27 Rogier, E. *et al.* *Plasmodium falciparum* *pfhrp2* and *pfhrp3* Gene Deletions and Relatedness  
521 to Other Global Isolates, Djibouti, 2019-2020. *Emerg Infect Dis* **28**, 2043-2050,  
522 doi:10.3201/eid2810.220695 (2022).  
523 28 Sepulveda, N. *et al.* Global analysis of *Plasmodium falciparum* histidine-rich protein-2  
524 (*pfhrp2*) and *pfhrp3* gene deletions using whole-genome sequencing data and meta-analysis.  
525 *Infect Genet Evol* **62**, 211-219, doi:10.1016/j.meegid.2018.04.039 (2018).  
526 29 Nair, S., Li, X., Nkhoma, S. C. & Anderson, T. Fitness Costs of *pfhrp2* and *pfhrp3* Deletions  
527 Underlying Diagnostic Evasion in Malaria Parasites. *J Infect Dis* **226**, 1637-1645,  
528 doi:10.1093/infdis/jiac240 (2022).  
529 30 Mok, S. *et al.* Mapping the genomic landscape of multidrug resistance in *Plasmodium*  
530 *falciparum* and its impact on parasite fitness. *bioRxiv*, doi:10.1101/2023.06.02.543338  
531 (2023).

532 31 Feleke, S. M. *et al.* *Plasmodium falciparum* is evolving to escape malaria rapid diagnostic  
533 tests in Ethiopia. *Nat Microbiol* **6**, 1289-1299, doi:10.1038/s41564-021-00962-4 (2021).  
534 32 Menegon, M. *et al.* Identification of *Plasmodium falciparum* isolates lacking histidine-rich  
535 protein 2 and 3 in Eritrea. *Infect Genet Evol* **55**, 131-134, doi:10.1016/j.meegid.2017.09.004  
536 (2017).

537

538

## 539 **Figure legends**

540 **Figure 1.** Map of Eritrea showing health facilities where samples were collected.

541 **Figure 2.** Prevalence of K13 mutations among health facilities, zones and overall. \*p<0.05;  
542 \*\*p <0.01.

543 **Figure 3.** Genetic relatedness of parasites carrying the *pfk13* R622I mutation (in pink) or  
544 wild type 622R (in green). Cut-off of 2 was used, in that only parasite haplotypes with  $\geq 5$   
545 identical alleles of the 7 markers tested were linked together.

546 **Figure 4.** Comparison of parasite density between *pfk13* R622I mutant and wild type 622R  
547 parasites. Left panel: Parasite densities in survey participants estimated by qPCR from DBS-  
548 derived DNA. Right panel: Parasite densities for participants from the severe malaria study,  
549 as estimated from blood films. Horizontal and vertical bars show median density and inter-  
550 quartile range.

551 **Figure 5.** Proportion of samples with and without *pfhrp2* and *pfhrp3* deletions.

